Chiesi Tackles Carbon Footprint Of Inhalers
Inks Propellant Deal With Koura
The Italian firm has laid out its ambitious plan to introduce the first carbon minimal pressurized metered dose inhaler for asthma and COPD by 2025 and secured supply of a new environmentally friendly propellant.
You may also be interested in...
AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.
The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.
The European Commission has backed J&J's blockbuster to treat children with psoriasis but the drug has fallen foul of NICE for ulcerative colitis.